AgeReset
Bio
AgeReset Bio is building the «DPC» technology platform for cellular rejuvenation and radical extension of healthy lifespan. Autologous dormant pluripotent cells — your own, functionally young, without Yamanaka factors and without the oncogenic iPSC pathway.
Mission
100+ years of combined experience. Scientists capable of taking science from lab to clinic.
01 · Problem
Aging affects cells, tissues, organs and the body as a whole. Modern pharmacology mostly treats age-related diseases one by one, but does not remove the overall age-related shift of tissues. Trying to target several lines of age-related pathology at once increases the complexity of therapy and compounds the risks of side effects.
Cell therapies are potentially closer to the body's natural repair mechanisms, but existing approaches hit three barriers — and the effect remains limited.
02 · Solution
AgeReset Bio develops autologous (own) cells obtained from an aged organism without Yamanaka factors and without the classic iPSC reprogramming pathway.
The platform's key testable hypothesis — absence of teratoma behavior while retaining pluripotent potential.
The patient's own — material is obtained from their own organism.
By assumed biological state — a young cellular reserve.
Pluripotent potential: the ability to give rise to derivatives of all tissues.
By the method of acquisition — without the oncogenic pathway of classic technologies.
03 · The DPC platform
Definition
We named the cells we obtained DPC — Dormant Pluripotent Cells. Unlike other types of pluripotent cells — iPSC and ESC — they are in a state of low spontaneous proliferation (division).
Main scientific hypothesis
If DPC truly combine autologous origin, universal pluripotent potential, a functionally young state and the absence of teratoma behavior — they can become the basis of a platform for safe cellular renewal of aged tissues.
04 · Why now
The first step from hypothesis to laboratory confirmation has already been taken. The team learned to obtain DPC in its own laboratory and formed the nearest testable plan of evidence for safety, universality and functionality.
Nearest value inflection
The key experiment tests the main risk of the entire pluripotent-cell field — teratoma formation. If DPC confirm pluripotency and at the same time do not form teratomas where control iPSC or ESC should demonstrate teratoma potential — this will create the basis for a new direction in cell rejuvenation technologies.
05 · What's already done
A sequential research program since 2019.
The team explored non-standard approaches to treating various cancers in the paradigm "cancer — an unfinished attempt of the body to rejuvenate," and raised about $1M of investment.
A scientific concept was put forward: full rejuvenation is impossible without a stage of pluripotency with oncogenic risks switched off.
The team researched ways to create young conditions for the cells of an aged organism. Two patents were obtained for products based on the secretome of stem cells from various sources.
In our own laboratory, DPC were obtained twice from an aged team member, without Yamanaka factors. Their signs of pluripotency were shown in vitro.
06 · Success criteria
By the standard protocol: the ability to differentiate into derivatives of all three germ layers.
DPC do not form teratomas by the standard protocol in an immunodeficient mouse model — unlike iPSC / ESC.
Quality control and karyotypic genomic stability — assessment of chromosome structure and number.
Functional, phenotypic and laboratory metrics in long-lived mice versus control.
DPC combined with plasmapheresis and young exosomes — a platform of cell technologies capable not only of improving health in old age, but of a testable increase in the maximum length of healthy life.
07 · Roadmap
From confirming DPC properties to a clinical program, personal cell banks, a partner network and long-term automation of individual cell therapy.
We show the safety and viability of DPC technology, fundamentally different from other cell technologies. The first bridge from theory to experimental results in the field of rejuvenation.
Safety, expansion, storage, dosing, routes of administration of DPC. Criteria for the body's response. Lifespan control, transcriptomic and epigenomic clocks. Preparing the preclinical package for the clinic. Patent coverage.
Transition to medical validation of the platform in humans.
De-identified data on biomarkers, safety, procedure frequency and individual response.
Procedures in jurisdictions where they are legally permitted, with medical supervision and biomarker collection. The basis of personalized therapy.
Creation, quality control, cryostorage and preparation of individual doses.
Granting clinics and cell laboratories the right to work under AgeReset Bio protocols.
Personalized cell automats and family mini-banks after clinical and regulatory validation.
08 · Investors
If DPC confirm pluripotency without teratomas — the company gains the basis for a new class of cell technologies for radical rejuvenation.
AgeReset Bio is building not a single procedure but an infrastructure of cellular rejuvenation: from the patient's own DPC bank and regularly repeated interventions to a licensed clinical network and future automation.
Not a single business model, but a platform with several monetization stages that switch on as risks are removed.
A scientific-investment model: the company proves safety, the absence of teratoma risk, DPC reproducibility and first efficacy metrics. The main value — growth of company value after each proven stage.
Regulated access for volunteers in permitted jurisdictions — with informed consent, medical supervision, adverse-event registration and biomarker collection.
A patient creates their own DPC bank once, then uses it every 6–12 months. Revenue: initial acquisition, quality control, cryostorage, subscription, dose preparation, repeat procedures, monitoring.
Granting clinics and laboratories the right to work under the protocol — scalable infrastructure. Revenue: licensing, training, certification, quality-control standards, royalties, lab audits.
The long-term peak. After standardization and regulatory clearance — personalized automated systems. Revenue: device sale/lease, consumables, service, software, remote quality control, protocol updates.
The long-term goal — to make cellular rejuvenation an accessible, manageable, repeatable and scalable medical infrastructure.
09 · Company & team
AgeReset Bio is based in San Diego, California — one of the world's largest biotechnology hubs. The company was founded in 2026 to develop a technology capable of extending the maximum healthy lifespan beyond existing biological limits.
The team holds a concept of aging, publications, patents and hands-on experience in stem-cell technologies, clinical cell processes and translational laboratory research.
CEO
25+ years in stem-cell biology, exosome technology, anti-aging therapy and cancer research. Former VP of Global Research at Stemedica Cell Technologies.
A distinguished Scientific Development executive with over 25 years of expertise in stem cell biology, exosome technology, anti-aging, and cancer research. Directed clinical and preclinical programs for over 300 patients across multiple indications.
CMO
Clinical lead. Stem-cell and plasmapheresis trials, clinic management. 30+ years studying the mechanisms of aging.
Head of Laboratory
Ex-Intrinsic Life Sciences. CLIA/CAP launches, $5M of clinical projects. 20+ publications.
Director of Laboratory Operations and Senior Scientist. A distinguished molecular biologist with over 20 years of expertise in high-complexity diagnostic assay development, regulatory compliance, and laboratory management. Former Director of Laboratory Operations at Intrinsic Life Sciences, where she oversaw global clinical testing projects generating $5M in revenue and led the facility to achieve CLIA certification and CAP accreditation.
Key qualifications: regulatory and operational leadership (CAP, ICH, GCLP); assay innovation and validation (high-complexity ELISA tests, biomarker assays with improved sensitivity and specificity); management of multi-million-dollar clinical trial projects; expertise in proteomics, mammalian cell culture and molecular biology. 20+ scientific publications.
Senior Scientist
UC San Diego · Salk · Max Planck. Publications in Cell, PNAS, EMBO J. Lifespan-extension patent.
Senior Research Scientist and Project Director. A distinguished molecular cell biologist with over 25 years of expertise in oncology drug discovery, stem cell biology and the biology of aging. Former Postdoctoral Fellow at The Salk Institute and Scientist at the Max Planck Institute; led research on protein phosphatases in glucose signaling and pioneered optogenetic control of Wnt signaling in organoids.
Inventor of a licensed patent (WO/2006/012304) on increasing life span through SMEK modulation. Ph.D. in Molecular Genetics & Signal Transduction (UC San Diego). Publications in Cell, PNAS and EMBO J.
Scientific Mentor
Best known for discovering the "Hoffman effect." Professor of Surgery at UC San Diego, founder of AntiCancer, Inc. Researcher of the methionine dependence of cancer cells and fluorescent imaging models; over 1,200 scientific publications.
10 · Terms in plain language
11 · Contact
Make cellular rejuvenation an accessible medical infrastructure.
AgeReset Bio is open to conversations with investors, clinical partners, cell laboratories and scientific organizations interested in advancing safe, personalized cell rejuvenation technologies.
AgeReset Bio — a company at the heart of global biotech, San Diego.
Eugene Baranov
CEO
San Diego, California
More · team development history
These materials relate to the team's early cancer research and are not directly related to the DPC platform. They are shown as the team's development history — confirmation that the team raised important non-standard questions and obtained partial results.
